Bio-thera Solutions

This early-stage study tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the body…

This study looked at how well and how safely QLETLI (a biosimilar of adalimumab) works for children and teenagers aged 4 to 17 with severe plaque psoriasis. A total of 80 participants were followed for 24 weeks. The main goal was to see if the drug could significantly reduce psor…

This early-stage study tested a new drug called BAT1308 in 59 adults with advanced solid tumors that did not respond to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. This is a…

This early-phase study tested a new drug called BAT7104 in 86 adults with advanced malignant tumors who had no other standard treatment options. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, and …

This study tested a new medicine called BAT5906 against a standard treatment (Lucentis) for wet age-related macular degeneration, a condition that can cause rapid vision loss. 488 adults aged 50-85 with active disease received either BAT5906 or Lucentis injections into the eye. T…

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors (including melanoma) who had no other treatment options. The main goal was to find a safe dose and check for side effects. This is not a cure; it aims to control the disease.

This early-phase study tested a new drug called BAT8010 in 23 people with advanced or metastatic solid tumors that had not responded to standard treatments. The main goals were to find the safest dose and check for side effects. Participants received one of eight different doses …

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…